Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Future MDS treatment options

Inga Mandac • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine

Inga Mandac, MD, Clinical Hospital Merkur, Zagreb, Croatia, discusses future priorities to focus on combinational treatments with targeted agents or monoclonal antibodies for myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Inga Mandac

2:51
MicroRNA signatures in MDS
Inga Mandac • 5 Mar 2020
3:04
Expanding MDS therapy options
Inga Mandac • 5 Mar 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals